Evotec (NASDAQ:EVO) Announces Quarterly Earnings Results

Evotec (NASDAQ:EVO) announced its quarterly earnings results on Wednesday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.06), FiscalAI reports. Evotec had a negative net margin of 21.24% and a negative return on equity of 18.20%. The firm had revenue of $297.02 million during the quarter, compared to the consensus estimate of $276.94 million.

Here are the key takeaways from Evotec’s conference call:

• Just Evotec Biologics pivoted to an asset‑light, technology‑enablement model highlighted by the $650m Sandoz agreement, an approximately €65m Q4 license contribution and 39.8% full‑year revenue growth, positioning JAB as a higher‑margin growth pillar.
• The Horizon transformation targets structural run‑rate savings of about €75m by end‑2027 (with ~20–30% realized in 2026), plus consolidation to 10 sites and commercial upgrades designed to lift adjusted EBITDA margin toward and beyond 20% by 2028.
• The Discovery & Preclinical Development (DMPD) segment saw continued softness—2025 revenues declined ~13.5% and segment adjusted EBITDA turned negative due to overcapacity—making DMPD a near‑term drag with recovery expected mainly in H2 2026.
• Evotec enters 2026 with a strong liquidity position (~€476m cash and no active covenants), but management’s 2026 guidance is cautious (group revenues €700–780m; adjusted EBITDA €0–40m), reflecting a transition year with execution and market‑recovery risk.

Evotec Stock Up 5.0%

NASDAQ:EVO traded up $0.13 during trading hours on Wednesday, reaching $2.71. The company’s stock had a trading volume of 85,814 shares, compared to its average volume of 137,506. The firm has a 50-day simple moving average of $3.05 and a 200-day simple moving average of $3.32. Evotec has a 1 year low of $2.31 and a 1 year high of $4.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Revenue came in ahead of expectations (Q results: $297.02M vs. $276.94M est.), signaling healthy top-line activity in Evotec’s services and partnership business — supports longer‑term commercial value. Press Release
• Positive Sentiment: Company disclosed a ~$100M deal alongside its results, which provides near-term revenue visibility and validates commercial partnerships. Investing.com: 2026 outlook & $100M deal
• Positive Sentiment: MAK Capital (activist investor) is pushing Evotec to list its U.S. unit (valued by MAK at >€1bn) — this could unlock hidden value if management follows through, a potential catalyst for re‑rating. MSN: MAK urges US listing
• Positive Sentiment: Board change: Evotec nominated industry veteran Dieter Weinand as Supervisory Board Chairman, signaling a push toward stronger commercial execution and governance — may reassure investors about strategic focus. AccessNewswire: Board nomination
• Neutral Sentiment: Evotec says it will continue dialogue with MAK Capital after MAK published a list of requested changes — ongoing engagement reduces immediate governance conflict but keeps activist pressure in play. Reuters: Engagement with MAK
• Neutral Sentiment: Analyst previews and the annual report commentary are circulating; these provide context but no single new data point likely to move the stock materially today. Yahoo Finance: Q4 preview
• Negative Sentiment: Earnings per share missed expectations ($0.05 vs. $0.11 est.), and Evotec reported negative net margin (‑21.24%) and negative ROE (‑18.20%) — profitability weakness raises short‑term concern despite revenue strength. MarketBeat: Earnings details & call
• Negative Sentiment: Company flagged a weak 2026 outlook after otherwise in‑line 2025 results — forward guidance weakness is likely the primary reason for investor caution and pressure on near‑term valuations. Investing.com: weak 2026 outlook

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Berenberg Bank assumed coverage on shares of Evotec in a report on Tuesday, February 3rd. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.00.

Hedge Funds Weigh In On Evotec

A number of large investors have recently added to or reduced their stakes in EVO. Wellington Management Group LLP raised its position in Evotec by 25.7% in the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after purchasing an additional 367,545 shares during the period. Jane Street Group LLC purchased a new position in Evotec in the 4th quarter worth $565,000. Millennium Management LLC purchased a new position in Evotec in the 4th quarter worth $317,000. Citadel Advisors LLC raised its position in Evotec by 186.1% in the 3rd quarter. Citadel Advisors LLC now owns 96,045 shares of the company’s stock worth $349,000 after purchasing an additional 62,471 shares during the period. Finally, OLD Mission Capital LLC purchased a new position in Evotec in the 4th quarter worth $158,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.